Evidence map›Paper›PMID 34597852›Full record

ArticleTransplantation and cellular therapy2022

Vitamin D deficiency after allogeneic hematopoietic cell transplantation promotes T-cell activation and is inversely associated with an EZH2-ID3 signature.

Rodney Macedo, Chloé Pasin, Alex Ganetsky, David Harle, Ximi K Wang, Kirubel Belay, Lee P Richman, Austin P Huffman, Robert H Vonderheide, Andrew J Yates and 4 more

Open access · greenAbstract read
In one paragraph

Article in Transplantation and cellular therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 5 institutions in 1 country.

Rodney MacedoColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.
Chloé PasinDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York.
Alex GanetskyDepartment of Pharmacy, Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania.
David HarleColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.
Ximi K WangColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.
Kirubel BelayColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, New York.
Lee P RichmanAbramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Austin P HuffmanColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, New York; Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Robert H VonderheideAbramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania; Abramson Cancer Center and the Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Andrew J YatesDepartment of Pathology and Cell Biology, Columbia University Irving Medical Center, New York, New York.
David L PorterAbramson Cancer Center and the Division of Hematology and Oncology, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, Pennsylvania.
Ying WangFels Institute for Cancer Research and Molecular Biology, Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, Pennsylvania.
Yi ZhangFels Institute for Cancer Research and Molecular Biology, Department of Microbiology and Immunology, Temple University School of Medicine, Philadelphia, Pennsylvania.
Ran ReshefColumbia Center for Translational Immunology, Department of Medicine, Columbia University Irving Medical Center, New York, New York. Electronic address: ran.reshef@columbia.edu.
Columbia University Irving Medical Center · USCancer Research Institute · USTemple University · USHospital of the University of Pennsylvania · USUniversity of Pennsylvania · US

Funding

UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Robert H. Vonderheide · 1985 to 2026
$222.3M
Tumor Biology and Microenvironment ProgramP30CA013696 · NCI · COLUMBIA UNIV NEW YORK MORNINGSIDE · PI Anil K Rustgi · 1985 to 2026
$115.3M
Modeling the development, structure and regulation of T cell memoryR01AI093870 · NIAID · UNIVERSITY OF GLASGOW · PI YATES, ANDREW · 2011 to 2025
$5.9M
Ezh2-mediated Epigenetic Effects and AlloimmunityR01HL127351 · NHLBI · TEMPLE UNIV OF THE COMMONWEALTH · PI ZHANG, YI · 2016 to 2019
$2.4M
Effector T-cell trafficking in graft-versus-host diseaseR01HL143424 · NHLBI · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI RESHEF, RAN · 2019 to 2023
$2.0M
NCI NIH HHS P30 CA013696NCI NIH HHS P30 CA016520NHLBI NIH HHS R01 HL127351NHLBI NIH HHS R01 HL143424NIAID NIH HHS R01 AI093870
6 · The paper itself

Abstract

Vitamin D promotes a shift from a proinflammatory to a more tolerogenic immune state in allogeneic hematopoietic cell transplant (HCT) recipients. The dominant mechanism responsible for this shift has not been elucidated. We took a multifaceted approach to evaluating the clinical and immunologic impact of low vitamin D levels in 53 HCT recipients. We used 28-plex flow cytometry for immunophenotyping, serum cytokine levels, T-cell cytokine production, and T-cell whole genome transcription. The median day-30 vitamin D level was 20 ng/mL, and deficiency was common in younger patients undergoing myeloablative transplantation. Low vitamin D levels were associated with a high CD8/Treg ratio, increased serum levels and T-cell production of proinflammatory cytokines, and a gene expression signature of unrestrained T-cell proliferation and epigenetic modulation through the PRC2/EZH2 complex. Immunophenotyping confirmed a strong association between high levels of vitamin D and an activated EZH2 signature, characterized by overexpression of ID3, which has a role in effector T-cell differentiation. Our findings demonstrate the critical role of vitamin D in modulating T-cell function in human GVHD and identify a previously undescribed interaction with EZH2 and ID3, which may impact effector differentiation and has implications to cell therapies and other forms of cancer immunotherapy. © 20XX American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

Indexed as

Graft vs Host DiseaseHematopoietic Stem Cell TransplantationVitamin D DeficiencyEnhancer of Zeste Homolog 2 ProteinHumansInhibitor of Differentiation ProteinsNeoplasm ProteinsTransplantation ConditioningTransplantation, HomologousEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanID3 protein, humanInhibitor of Differentiation ProteinsNeoplasm ProteinsAcute graft-versus-host diseaseAllogeneic hematopoietic cell transplantationEpigenetic regulationT-cell functionVitamin D

Identifiers

PMID34597852
PMCPMC8792200
OpenAlexW3202601466

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.